Agilent Tech

Q3 FY2026 EarningsQ3 FY26 results exceeded consensus across all key financial metrics, with revenue of $1,878M vs. $1,841M expected (+2.0%) and normalized EPS of $1.55 (derived) surpassing the $1.49 mean. The top-line beat was driven by 11% growth in Life Sciences and Diagnostics (LSAG), bolstered by the $950M Biocare acquisition. Gross margin showed significant expansion to 55.5% vs. 54.3% expected, aided by a 1 pct operating margin benefit from tariff refunds and supply chain optimization.